Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 8/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.42 |
| ▸ | IDH2 | P48735 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PAK4 | O96013 | 1/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10312180 | 0.93 | HRH4 (0.48) | HRH4IGF1RCCNA2CDK2CCNA1 | |
| SCHEMBL10312080 | 0.91 | IDH2 (0.51) | HRH4IGF1RCCNA2CDK2CCNA1 | |
| SCHEMBL10312076 | 0.90 | HRH4 (0.59) | USP2SMN1; SMN2HRH4IGF1RCCNA2 | |
| SCHEMBL10312174 | 0.90 | HRH4 (0.46) | USP2SMN1; SMN2HRH4IGF1RCCNA2 | |
| SCHEMBL10312157 | 0.89 | IGF1R (0.47) | HRH4IGF1RPAK4PAK1 | |
| SCHEMBL10312075 | 0.88 | USP2 (0.50) | USP2SMN1; SMN2HRH4IDH2MAPT | |
| SCHEMBL10312131 | 0.88 | IGF1R (0.47) | HRH4IGF1RPAK4PAK1PIK3CA | |
| SCHEMBL16556847 | 0.88 | IGF1R (0.47) | IGF1RPAK4PAK1 | |
| SCHEMBL10312233 | 0.88 | HRH4 (0.56) | USP2SMN1; SMN2HRH4IGF1RCCNA2 | |
| SCHEMBL10312226 | 0.88 | HRH4 (0.47) | USP2SMN1; SMN2HRH4IGF1RCCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440055-B1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY LLC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | STK25, STK35, SGK2 | USP2 1096/4885SMN1; SMN2 2127/4885HRH4 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.